Craig Mundie logo

Craig Mundie

Description

Craig Mundie is chief research and strategy officer of Microsoft Corp., reporting to CEO Steve Ballmer. In this role, he oversees Microsoft ...

Investor Profile

Craig Mundie has made 4 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series Unknown (25%)
  • Series B (25%)
  • Seed (25%)
  • Series C (25%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Life Science
  • Genetics
  • Therapeutics
  • Chemical
  • Nanotechnology
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Craig Mundie frequently co-invest with?

Kairos Ventures
North America, California, United States, Beverly Hills
Co-Investments: 1
Co-Investments: 1
AB
North America, Illinois, United States, Lake Forest
Co-Investments: 1
AbbVie Biotech Ventures
North America, Illinois, United States, North Chicago
Co-Investments: 1
Tempus
North America, Illinois, United States, Chicago
Co-Investments: 1
KS
North America, New York, United States, New York
Co-Investments: 1

Which angels does Craig Mundie often collaborate with?

PG
North America, Illinois, United States, Chicago
Shared Deals: 1
David R. Walt
North America, Massachusetts, United States, Boston
Shared Deals: 3
ES
North America, California, United States, Mountain View
Shared Deals: 1
BG
North America, Washington, United States, Seattle
Shared Deals: 2
Shared Deals: 1
PR
North America, Colorado, United States, Denver
Shared Deals: 2
HE
North America, Maryland, United States, Baltimore
Shared Deals: 1
JA
North America, Texas, United States, Austin
Shared Deals: 1
MT
North America, New York, United States, New York
Shared Deals: 1
EL
North America, Illinois, United States, Chicago
Shared Deals: 1

What are some of recent deals done by Craig Mundie?

Stoicheia

Skokie, Illinois, United States

Stoicheia is a nanotechnology company accelerating materials discovery by defining and expanding the materials genome.

BiotechnologyChemicalLife ScienceNanotechnology
SeedJan 27, 2019
Amount Raised: $5,000,000
Exicure

Chicago, Illinois, United States

Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets.

BiotechnologyGeneticsLife ScienceTherapeutics
Series UnknownSep 27, 2017
Amount Raised: $20,000,000
Exicure

Chicago, Illinois, United States

Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets.

BiotechnologyGeneticsLife ScienceTherapeutics
Series CJun 17, 2014
Amount Raised: $13,600,000
Exicure

Chicago, Illinois, United States

Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets.

BiotechnologyGeneticsLife ScienceTherapeutics
Series BDec 21, 2011
Amount Raised: $5,400,000